Q1 2025 13F Holders as of 3/31/2025
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
53.1M
-
Number of holders
-
83
-
Total 13F shares, excl. options
-
34.8M
-
Shares change
-
-6.26M
-
Total reported value, excl. options
-
$21.7M
-
Value change
-
-$4.3M
-
Put/Call ratio
-
1.09
-
Number of buys
-
33
-
Number of sells
-
-38
-
Price
-
$0.62
Significant Holders of ALX ONCOLOGY HOLDINGS INC - Common Stock, par value $0.001 per share (ALXO) as of Q1 2025
99 filings reported holding ALXO - ALX ONCOLOGY HOLDINGS INC - Common Stock, par value $0.001 per share as of Q1 2025.
ALX ONCOLOGY HOLDINGS INC - Common Stock, par value $0.001 per share (ALXO) has 83 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 34.8M shares
of 53.1M outstanding shares and own 65.49% of the company stock.
Largest 10 shareholders include venBio Partners LLC (9.7M shares), Redmile Group, LLC (3.64M shares), TANG CAPITAL MANAGEMENT LLC (3.16M shares), BlackRock, Inc. (2.31M shares), VANGUARD GROUP INC (1.84M shares), BANK OF AMERICA CORP /DE/ (1.45M shares), Almitas Capital LLC (1.35M shares), ACADIAN ASSET MANAGEMENT LLC (1.3M shares), MILLENNIUM MANAGEMENT LLC (944K shares), and GEODE CAPITAL MANAGEMENT, LLC (771K shares).
This table shows the top 83 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.